Omeros Corporation (OMER) - Stock Analysis
Last updated: Apr 5, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Omeros Corporation is a high-conviction hot idea driven by the transformative FDA approval of YARTEMLEAÂŽ (first approved treatment for TA-TMA), an 80%+ stock surge to 12-month highs, strategic capital infusion via license deal with Novo Nordisk, and strong near-term commercial launch prospects starting 2026.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Zero revenue ⢠High leverage ⢠Positive quarter OMER shows troubling fundamentals â zero reported revenue and heavy cash burn with negative equity and large long-term debt despite quarter-level profits, adequate short-term liquidity, and substantial tangible/investment assets.
Price Behavior
Key Price Behavior Insights: ⢠Mild downward bias ⢠Neutral momentum ⢠Elevated volatility Support Level: $9.81 Resistance Level: $12.08 Slight short-term weakening over the last month with price sitting just below the ~ $10.99 SMA, neutral momentum (RSI ~48), key resistance near $12.08 and support at $9.81, and a sharp uptick into 2026-04-01 followed by a pullback that raises short-term whipsaw risk.
Sentiment & News
Key News Insights: ⢠Oneâtime gain ⢠Yartemlea launch ⢠Market momentum Omeros swung to Q4 profit driven by a roughly $238M oneâtime zaltenibart rights gain that cut debt and boosted cash, while advancing Yartemlea commercialization amid strong market activity and analyst optimism tempered by pricing/competitive risks.
AI Summary
OMER has shifted from a pure development biotech to a balance-sheet-derisked, early-commercial company where the investment hinges on two specific execution pointsâcan Yartemlea convert initial hospital/distributor shipments into repeatable, reimbursed revenue (NTAP/CPT adoption) and will licensing proceeds be realized and allocated to meaningfully reduce debtâbecause failure on either front quickly reintroduces solvency and dilution risk.
Description
Omeros Corporation is a commercial-stage biopharmaceutical company that develops small-molecule and protein therapeutics for inflammation, complement-mediated disorders, immune-related cancers, and addictive or compulsive disorders. Its pipeline spans late-stage assetsâmost notably a MASP-2 antibody that has completed a pivotal study for HSCTâTMA and is in Phase III for IgA nephropathy and aHUSâthrough earlier clinical programs and preclinical work on MASP-targeted small molecules, longer-acting antibodies, GPCR targets, and cell therapies. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 29 | Jan 5 | OMER | Omeros Corporation | Omeros Corporation is a high-conviction hot idea driven by the transformative FDA approval of YARTEMLEAÂŽ (first approved treatment for TA-TMA), an 80%+ stock surge to 12-month highs, strategic capital infusion via license deal with Novo Nordisk, and strong near-term commercial launch prospects starting 2026. | Closed | -7.1% |